A Multicenter, Randomized, Outcomes Assessor Blind, Parallel Controlled Trial to Evaluate the Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After Coronary Artery Bypass Grafting

The goal of this clinical trial is to to evaluate the effect of oral isosorbide mononitrate plus amlodipine antispasm therapy on outcomes of radial artery grafts in patients underwent primary isolated CABG.
The main question it aims to answer is:
Whether the oral isosorbide mononitrate plus amlodipine antispasm therapy could reduce the occlusion outcome of radial artery grafts after CABG .
Researchers will compare isosorbide mononitrate plus amlodipine to none to see if isosorbide mononitrate plus amlodipine works.
Participants will
1. Take oral isosorbide mononitrate (20-40mg daily) plus amlodipine (2.5-5mg daily) therapy for 24 weeks after CABG.
2. Clinical follow-up at Week 1, 4, 12, and 24 after CABG.
3. Protocol-driven CCTA at Week 24 after CABG.

Start Date01 Jun 2025

Sponsor / Collaborator

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

ISRCTN44436843

/ RecruitingPhase 3IIT

The LACunar Intervention Trial 3 (LACI-3). Assessment of efficacy and safety of cilostazol and isosorbide mononitrate to prevent adverse outcomes in patients with cerebral small vessel disease (lacunar) ischaemic stroke.

Start Date03 Mar 2025

Sponsor / Collaborator

The University of Edinburgh

[+1]

NCT06715007

/ Not yet recruitingNot ApplicableIIT

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

Cerebral small vessel disease (cSVD) is a common accompaniment of aging. Recent small subcortical (or lacunar) infarcts (i.e. symptomatic cSVD) and white matter hyperintensities are typical cSVD lesions on neuroimaging. cSVD causes about a quarter of ischaemic strokes and related with cognitive dysfunction. However, few studies are available so far to especially explore the treatment of cSVD. Endothelial dysfunction plays an important part in cSVD. Cilostazol and isosorbide mononitrate have endothelial protective function. We designed this prospective cohort study in China, aiming to evaluate the effect of different antiplatelet agents (e.g. Cilostazol) on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).

Start Date20 Dec 2024

Sponsor / Collaborator

Jiangsu Provincial People's Hospital

100 Clinical Results associated with Isosorbide Mononitrate

100 Translational Medicine associated with Isosorbide Mononitrate

100 Patents (Medical) associated with Isosorbide Mononitrate

1,069

Literatures (Medical) associated with Isosorbide Mononitrate

01 Feb 2025·EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Peripheral edema induced by isosorbide mononitrate in an elderly patient: A case study of dose-related risks and drug interactions

Article

Author: Vyas, Bhavin A ; Desai, Bhargavi V ; Pandit, Akansha A

Adverse drug reactions (ADRs) in elderly patients are frequently attributed to age-related altered pharmacokinetics and the complexities of polypharmacy to manage multiple chronic conditions, making elderly patients more susceptible to ADRs. The following is a case report of an 80-year-old female patient with systemic symptoms of chest pain, low blood sugar, mouth ulcers, and concentrates on peripheral edema due to nitrate vasodilator isosorbide mononitrate (ISMN). She had hypertension, diabetes, ischemic heart disease, and chronic obstructive pulmonary disease (COPD).On the third day of therapy, she exhibited peripheral edema, prompting the initiation of furosemide and the cessation of ISMN; the patient's condition markedly improved. ISMN primarily reduces preload by inducing venodilation, which leads to blood pooling and hence peripheral edema. The simultaneous administration of other contributing drugs like antifungal agent fluconazole which can potentiate the ADR by elevating plasma levels of ISMN, leading to an enhanced vasodilatory impact. The evaluation conducted using the modified Schumock and Thornton scale classified the adverse medication response as likely, of moderate intensity, and avoidable. This example emphasizes the need of vigilant monitoring of adverse drug responses in the elderly patients, with importance of dosage modifications as well as highlights cautious prescribing of contributing drugs to prevent ADRs.

09 Jan 2025·JOURNAL OF MEDICINAL CHEMISTRY

Hypoxia Activated Nitric Oxide Donor Compounds for the Prevention and Treatment of Myocardial Hypoxia-Induced Injury

Article

Author: Zhou, Wen ; Yang, Wanxiang ; Gou, Shaohua

A series of hypoxia-targeted nitric oxide donor compounds were designed and synthesized by using an ether linker to connect N-methyl-N-nitroso-p-phenol and nitrobenzyl alcohols, respectively. Among them, N6, with acceptable pharmacokinetic parameters in mice, exhibited a high selective NO release in H9c2 cells under hypoxia and in the dissected heart tissue of the tested mice as desired. Mechanistic investigations revealed that N6 could regulate vascular dilation and modulate proteins associated with myocardial injury both in vitro and in vivo. Animal tests demonstrated that N6 showed better therapeutic and preventive effects against myocardial hypoxia injury than the commercial drug isosorbide mononitrate. Our research evidence that N6 has a potent therapeutic potential in treating myocardial hypoxic injury, which can be further investigated as a promising drug candidate for coronary heart disease.

01 Jan 2025·EXPERIMENTAL NEUROLOGY

Combination treatment with cilostazol and isosorbide mononitrate attenuates microemboli-mediated vascular cognitive impairment and improves imaging and plasma biomarkers in diabetic rats

Article

Author: Li, Alice A ; Voltin, Joshua ; Edwards, Jazlyn ; He, Lianying ; Li, Weiguo ; Falangola, Maria Fatima ; Ergul, Adviye ; Jamil, Sarah ; Karakaya, Eda ; Abdelsaid, Kareem ; Li, Alice A. ; Nie, Xingju

Diabetes is a major risk factor for all types of dementia. The underlying reasons are not fully understood, and preventive therapeutic strategies are lacking. Previously we have shown that diabetic but not control rats developed a progressive cognitive decline in a microemboli (ME) model of vascular contributions to cognitive impairment & dementia (VCID). Given the cerebrovascular dysfunction is a mutual pathological change between diabetes and VCID, we hypothesized that the cognitive impairment in this ME model can be prevented by improving the endothelial function in diabetes. Our treatment paradigm was based on the LACI-2 Trial which assessed the efficacy of isosorbide mononitrate (ISMN) and cilostazol (Cil) treatments in small vessel disease progression. Control and diabetic rats were treated with ISMN/Cil or vehicle for 4 weeks, then injected with cholesterol crystal ME and the behavioral outcomes were monitored. Brain microstructure integrity was assessed by diffusion MRI. Plasma biomarkers were assessed using angiogenesis, neurology and amyloid β 42/40 panels recommended by the MarkVCID consortium. Behavioral deficits and the loss of tissue integrity previously observed in untreated diabetic rats were not noted in the treated animals in this study. Treatment improved tissue perfusion but there were no differences in plasma biomarkers. These results suggest that restoration of endothelial function with ISMN/Cil before ME injection prevented the possible deleterious effects of ME in diabetic rats by improving the endothelial integrity and it is a practical preventive and therapeutic strategy for VCID.

News (Medical) associated with Isosorbide Mononitrate

21 Jan 2025

·www.globenewswire.com

Press Release: Opella reaches study milestone for Cialis

Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to support the switch of Cialis (tadalafil) from a prescription to an over-the-counter medicine. This decision allows for the initiation of the AUT and makes Cialis the first PDE-5 inhibitor to achieve this milestone. AUTs evaluate the use of the medicine under real-world conditions to identify any issues that have not previously been identified and to confirm that consumers can self-diagnose and treat themselves appropriately without the help of a healthcare provider. Julie Van OngevallePresident and CEO, Opella“We are pleased that the FDA has completed their review and is allowing us to initiate this important study. The actual use trial is not only a significant opportunity to gain insights into how Cialis is used by consumers without a prescription, but it also underscores our commitment to advancing self-care solutions. It represents a crucial step towards our commitment to make self-care as simple as it should be.” Dr. Josephine FubaraChief Science Officer, Opella“FDA’s decision marks a significant step forward in Opella’s data-driven efforts to switch a PDE-5 inhibitor like Cialis. Now that the FDA has completed their thorough review of our data, we can move into the next phase of this program; the actual use trial, which is pivotal in ensuring the safety and proper self-selection of Cialis for over-the-counter use. We look forward to continuing our work to bring safe and expanded access to the many consumers who will benefit from nonprescription Cialis.” Opella remains committed to advancing its development program and bringing a new self-care solution with proven effectiveness for people living with erectile dysfunction. The company is completing the clinical and regulatory activities necessary to initiate the pivotal AUT. Information about the study will become available on clinicaltrials.gov. On October 21, 2024 Sanofi and CD&R announced the intention to transfer a 50% controlling stake in Opella to CD&R with Sanofi to remain a significant shareholder. About CialisCialis (tadalafil) in the US is currently only available with a prescription. Cialis is a tablet taken to treat erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH), and both ED and the signs and symptoms of BPH. Cialis is the only PDE-5 inhibitor treatment that offers men a choice when it comes to treatment for ED - Cialis for use as needed and Cialis for once daily use. To learn more about Cialis, visit www.cialis.com. Cialis is not for women or children. It is important to note that Cialis is not to be taken with medicines called nitrates such as isosorbide dinitrate or isosorbide mononitrate which are often prescribed for chest pain; or with recreational drugs called poppers like amyl or butyl nitrite, as the combination may cause an unsafe drop in blood pressure; or if allergic to Cialis or Adcirca (tadalafil), or any of its ingredients. Anyone who experiences any symptoms of an allergic reaction, such as rash, hives, swelling of the lips, tongue or throat, or difficulty breathing or swallowing, should call a healthcare provider or get help right away. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Sanofi Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com Evan Berland | +1 215 432 0234 | evan.berland@sanofi.comNicolas Obrist | +33 6 77 21 27 55 | nicolas.obrist@sanofi.com Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.comVictor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com Opella Media RelationsJustine Rohée | +33 6 86 47 85 60 | justine.rohee@sanofi.com Sanofi Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | thomas.larsen@sanofi.comAlizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com Felix Lauscher | +1 908 612 7239 | felix.lauscher@sanofi.comKeita Browne | +1 781 249 1766 | keita.browne@sanofi.com Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com Tarik Elgoutni | +1 617 710 3587 | tarik.elgoutni@sanofi.comThibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press_Release

16 Aug 2024

·www.prnewswire.com

Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement

OSLO, Norway, Aug. 16, 2024 /PRNewswire/ -- In first half of 2024, Navamedic ASA (OSE: NAVA) , a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 277.2 million, up 12.8 per cent from the corresponding period last year. Adjusted EBITA amounted to NOK 41.1 million compared to NOK 26.3 million in 2023. The milestone payment of NOK 22.7 million following the agreement with Orion Corporation to market and sell Flexilev® and OraFID® in Europe is included. During the first six months of 2024, Navamedic has delivered on its strategy across the business. Following the launch of Eroxon® at the start of the year, the company renewed its contract with the Norwegian Hospital Procurement Trust, whereby Navamedic will continue to supply Norwegian hospitals with antibiotics until 2027. This agreement is expected to contribute more than 20 per cent revenue growth to the overall antibiotics' portfolio. In June, Navamedic signed a license and supply agreement with Orion Corporation (Orion) to market and sell Flexilev® and OraFID® in Europe. This agreement represents a major milestone in Navamedic's commercialisation strategy for Flexilev®. Orion has paved the way for Parkinson's disease treatment in Europe, making it a strong commercial partner for Navamedic. "Halfway into 2024, Navamedic can look back at an exciting first six months. There has been a lot of activity across the business, which has broadened Navamedic's geographical reach and product portfolio. Having been early to identify treatment areas with significant medical need and consumer demand, such as supplying antibiotics to hospitals and obesity, we have seen good growth across our key business areas: RX, Consumer and Hospital," said Kathrine Gamborg Andreassen, CEO of Navamedic ASA. Operating results (EBIT) for the first six months of 2024 amounted to NOK 33.8 million, compared to NOK 9.9 million in 2023. Operating costs ended at NOK 77.8 million, compared to NOK 74 million last year. Net financial items ended at negative NOK 9.7 million and profit before tax was NOK 24 million. Key figures and category update for the second quarter of 2024 Revenues for the second quarter amounted to NOK 156.3 million, up 26.2 per cent from last year. Adjusted EBITDA amounted to NOK 32.7 million, up from NOK 10.5 million in the second quarter of 2023. Gross margin for the quarter was 46.1 per cent, compared to 40.4 per cent in 2023. During the quarter, the company experienced steady growth across its three segments: Prescription Drugs (RX), Hospital and Consumer Health. As part of the Prescription Drugs (RX) category, sales of Mysimba® have remained stable in an increasingly competitive market. Imdur® and Forlax® have seen double digit growth year-over-year. Within the Hospital category, the antibiotics portfolio has delivered solid growth. The medical nutrition portfolio continues to deliver steady growth, delivering treatments for patients with Inborn Errors of Metabolism, which is considered a lifelong genetic disorder. In the Consumer Health category, Eroxon® was launched in Sweden in May, making it the first and only non-prescription treatment for erectile dysfunction in the country. It has also been a strong quarter for several hero products, including Absolut Torr and GeloRevoice, which are up 38 per cent and 35 per cent year-over-year, respectively. ThermaCare and Modifast continue to deliver stable sales. Navamedic plans to explore opportunities to expand both Absolut Torr and MedMade outside the Nordics Outlook Navamedic continues to see strong growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company. "We continue to build on a solid foundation and are exploring further opportunities for market expansion with our own products. A key driver for everyone at Navamedic is to be a proud contributor to public health, which includes identifying treatments and products that can enhance people's quality of life and ensuring that they are accessible, either through hospitals or pharmacies," Andreassen concluded. Presentation Navamedic will present the results for the second quarter and first half of 2024 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be webcast at the following link: Note: EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section in the attached presentation. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit Navamedic.com. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. This information was brought to you by Cision The following files are available for download:

License out/inFinancial Statement

15 Feb 2024

·www.prnewswire.com

Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives

OSLO, Norway, Feb. 15, 2024 /PRNewswire/ -- Navamedic ASA (OSE: NAVA) , a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was up 34 per cent to NOK 512 million, mainly by organic growth. For the first time all three product categories were above the NOK 100 million mark. The company's gross margin was 38.9 per cent for the year, down from 42.8 per cent in the year before. Adjusted EBITDA (EBITDA less acquisition cost) amounted to NOK 51.6 million, compared with NOK 51.7 million in 2022. Operating results (EBIT) amounted to NOK 23.6 million, compared to NOK 44.4 million in 2022. Operating costs were higher than in 2022, mostly due to continued investments in growth initiatives. Also included in the EBITDA is a negative contribution of 4.8 MNOK from the Sensidose business. "We are looking back at an eventful and transformative year. With the Sensidose acquisition, we gained a promising position in the market for treatment of Parkinson's Disease, and we renewed and secured new marketing and distribution agreements for several other high selling products, including Eroxon®, a clinically proven treatment of erectile dysfunction. Eroxon® was launched in Norway this week and will soon also be available in Sweden," said Kathrine Gamborg Andreassen, CEO of Navamedic. "Furthermore, in the fourth quarter 2023, we signed a term sheet with the Finnish pharmaceutical corporation Orion Pharma, which we are currently finalising into an agreement for a licensing and supply of Flexilev® and OraFID® in Europe, products that were acquired through Sensidose. In Sweden, Norway and Denmark, we will market and sell these products from our own proven platform," Andreassen added. Revenues in the fourth quarter of 2023 was NOK 125 million, up 8.1 percent from the same period last year. Gross margin was 36.5 per cent, down from 42.9 per cent, and Adjusted EBITDA was NOK 7.9 million, compared with NOK 15.7 million in the fourth quarter of 2022. Category update In the Consumer Health category, Modifast cemented its position with continued strong sales in Sweden, and Absolute Torr gained traction with a 54 per cent growth year-over-year in the fourth quarter. Further growth to be achieved through combination of consumer and pharmacy engagement, sale of unique and profitable products in home markets and out-licensing of own products elsewhere. The Hospital category saw double-digit growth year-over-year across the portfolio of antibiotics and medical nutrition products. It also renewed exclusive rights to Vitaflo's medical nutrition products across the Nordic for five more years. Winning new antibiotic tenders is core in the growth strategy, along with initiatives to expand and secure new marketing authorisations. The Prescription Drugs category had strong growth across various therapeutic areas, with continued high demand for Mysimba for obesity treatment, and strong sales of Imdur, Nitrolingual and Forlax. In this category, Navamedic is now preparing rollout of Flexilev with MyFID® and OraFID® in the Nordic countries and out-licensing in the rest of Europe. Outlook Navamedic sees continued strong growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company with a 15 per cent EBITDA margin. "We are building on a solid foundation. We will continue to strengthen our existing business by leveraging our highly scalable market access platform. We will explore opportunities for market expansion with own products and increase company value by acquiring and strengthening own products and brands while increasing gross margins through careful management of our product portfolio," Andreassen concluded. Navamedic will present the results for the fourth quarter and full year 2023 at 08.30 today. The presentation will take place at Dronning Eufemias Gate 16 in Oslo, and will be available to follow via webcast at the following link: Representatives from Navamedic's management team, CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation. EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section of the attached presentation on slide 23. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit Navamedic.com. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. The following files are available for download:

AcquisitionLicense out/in

100 Deals associated with Isosorbide Mononitrate

External Link

KEGG	Wiki	ATC	Drug Bank
D00630	Isosorbide Mononitrate	C01DA14	DB01020

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	CN	Livzon Group Livzon Pharmaceutical Factory	01 Jan 1993
Angina Pectoris	US	Promius Pharma LLC	30 Dec 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Angina, Stable	Phase 3	BR	Laboratórios Baldacci SA	01 Jul 2014
Myocardial Infarction	Phase 1	CN	-	10 Oct 2013
Vasospasm	Phase 1	CN	-	10 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03451591 (LACI-2, CTgov)	Phase 2/3	Stroke, Lacunar	363	Isosorbide Mononitrate XL (ISMN) (Isosorbide Mononitrate XL (ISMN))	ckixxqgmxf(eetbxeksdu) = kdwdwbrsey cdzfmgvbvx (aluylzpjrs, xvdvwbvygf - ijzlzozfzx) View more	-	12 Nov 2024
				Cilostazol (Cilostazol)	ckixxqgmxf(eetbxeksdu) = nfigoxvxcj cdzfmgvbvx (aluylzpjrs, ohiltkcxtz - inafkkouyf) View more
NCT04310995 (ASRAB-pilot, ESC2024)	Phase 4	complication of coronary artery bypass graft	150	Nicorandil 15 mg daily	kjrktlwkiq(djanlgpilq) = vughbcwflc xzysjfyjsf (onkqtjsmja ) View more	Negative	30 Aug 2024
				Isosorbide mononitrate 50 mg daily	kjrktlwkiq(djanlgpilq) = fvjkxkahfg xzysjfyjsf (onkqtjsmja ) View more
NCT04051957 (CTgov)	Phase 2	Acute Kidney Injury \| Proteinuria \| Hypertension	9	Isosorbide Mononitrate (Isosorbide Mononitrate)	aoxghjcaug(noeneqguvw) = ofavaibaid htddnzoqxn (ereoixlksw, bsmnzbpnov - vqvdxjibee) View more	-	03 Aug 2022
				Placebo oral tablet (Placebo)	aoxghjcaug(noeneqguvw) = qniucctkxr htddnzoqxn (ereoixlksw, qecmheadpy - grhogrgtst) View more
NCT02791906 (CTgov)	Phase 2	Chronic Kidney Diseases	8	ISMN (ISMN Only)	xnzfjftgjx(pwqnkxigxm) = ltqmyiehuc lrrzvxbaiy (gnzmyezpsr, byfaagnlxs - hwkazrnyij) View more	-	13 Aug 2020
				Vitamin C+ISMN (ISMN AND Vitamin C)	xnzfjftgjx(pwqnkxigxm) = gkladudkol lrrzvxbaiy (gnzmyezpsr, shxibszzab - thycncnyjm) View more
NCT02053493 (NEAT-HFpeF, CTgov)	Phase 2	Heart Failure	110	Placebo+Isosorbide Mononitrate (Isosorbide Mononitrate Crossover to Placebo)	jqkwvpnoca(iexwfzyyps) = zyapaczwet ewyyixtdlt (auxqrxxmqy, hhiutuqlhn - bfqprpwmrp) View more	-	28 Nov 2016
				Placebo+Isosorbide Mononitrate (Placebo Crossover to Isosorbide Mononitrate)	jqkwvpnoca(iexwfzyyps) = ofwpdmndtt ewyyixtdlt (auxqrxxmqy, mkgfkpfrza - bqysuvynzd) View more
NCT02053493 (Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 2	Heart Failure	110	Isosorbide Mononitrate	yynnoqwmpy(ekyghniiho) = jwabqcjils cxbeoodcjn (pkcuxqcvql, -780 to 17) View more	Negative	10 Dec 2015
				Placebo	-
NCT01430780 (Pubmed \| Coron Artery Dis)	Not Applicable	Coronary Artery Disease	60	ISMN 20 mg retarded release	jnayvjozfz(idipdjvuto) = uxbdxdixqg xceqhiowjn (htthhmkeha )	Negative	01 Nov 2013
				Placebo	jnayvjozfz(idipdjvuto) = vmxiykzvsb xceqhiowjn (htthhmkeha )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis